Eton Pharmaceuticals, Inc. (ETON)

Market Cap	93.13M
Revenue (ttm)	35.30M
Net Income (ttm)	913,000
Shares Out	25.69M
EPS (ttm)	0.04
PE Ratio	90.50
Forward PE	44.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,457
Open	3.700
Previous Close	3.650
Day's Range	3.610 - 3.700
52-Week Range	2.420 - 5.810
Beta	1.19
Analysts	Strong Buy
Price Target	9.00 (+148.62%)
Earnings Date	May 9, 2024

About ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortison...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 13, 2018
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: ETON

Financial Performance

In 2023, ETON's revenue was $32.64 million, an increase of 42.60% compared to the previous year's $22.89 million. Losses were -$936,000, -89.62% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for ETON stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 148.62% from the latest price.

Price Target

$9.0

(148.62% upside)

Analyst Consensus: Strong Buy